Dr. Patrick Forde, MD

Dr. Forde practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Forde's NPI, 1467733113, was assigned on September 7, 2011. Dr. Forde holds Maryland license UNLICENSED.

Dr. Forde's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Forde's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Forde to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Forde practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Forde's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Forde is licensed in Maryland.

CMS data shows 140 Medicare services from Dr. Forde across 2 procedure codes in 2024, all of them office visits, for 78 Medicare patients. Medicare paid $16,341 for them.

CMS counts 78 Medicare patients who saw Dr. Forde in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Forde's median patient age at 71, with 50% women.

In 2024, Dr. Forde wrote 145 Medicare Part D claims for 27 patients. 55% of them were for generic drugs. CMS names the drug for 78 of them, across 4 drugs with 11 or more claims each, at $873,678 in total drug cost. In 2023, CMS named 89 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Forde for performance year 2024, reported as part of a group.

Dmand AI links 153 papers to Dr. Forde, published from 2012 to 2025. 2023 was the busiest year, with 17. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Immunotherapy. Dr. Forde has published most often in J Immunother Cancer. Dr. Forde's most frequent co-authors are Jarushka Naidoo, BAO, BCH, MB, Josephine Feliciano, MD and Christine Lee Hann, MD, PhD.

Dmand AI links Dr. Forde to 11 clinical trials, 4 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Mesothelioma, Malignant. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Forde that name 1 trial.

CMS Open Payments shows 340 general payments to Dr. Forde from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. AstraZeneca Pharmaceuticals LP paid the most, $67,878. It also lists 3 research payments totaling $951 in 2023, naming 1 clinical trial.